Screener
Cytek Biosciences, Inc. CTKB Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $48.14M+5.6% | $44.14M+6.5% | $62.14M+8.1% | $52.29M+1.5% | $45.6M-2.2% | ||
| $19.8M-8.9% | $22.88M+7.4% | $29.26M+22.8% | $24.74M+10.0% | $21.74M+2.6% | ||
| $28.34M+18.7% | $21.25M+5.4% | $32.89M-2.3% | $27.55M-5.0% | $23.87M-6.2% | ||
| 58.9%+6.5pp | 48.2%-0.5pp | 52.9%-5.6pp | 52.7%-3.6pp | 52.3%-2.2pp | ||
| $9.74M+10.4% | $9.6M-1.2% | $8.96M-7.8% | $8.96M-9.4% | $8.83M-11.7% | ||
| $13.17M+8.6% | $11.65M-6.9% | $13.13M+10.6% | $11.67M-6.1% | $12.13M-1.1% | ||
| $16.83M+24.3% | $18.47M+43.2% | $16.39M+80.7% | $16.12M+47.3% | $13.53M+15.7% | ||
| $39.74M+15.2% | $39.72M+13.1% | $38.48M+25.5% | $36.74M+10.5% | $34.49M+1.6% | ||
| -$11.4M-7.3% | -$18.46M-23.3% | -$5.59M— | -$9.19M-116% | -$10.62M-24.6% | ||
| -23.7%-0.4pp | -41.8%-5.7pp | -9%— | -17.6%-9.3pp | -23.3%-5.0pp | ||
| $281K-32.1% | $262K-10.0% | —— | $494K+315% | $414K+209% | ||
| -$243K-106% | $1.09M-70.6% | $1.56M-78.7% | $1.42M-67.7% | $3.85M+187% | ||
| $515K+143% | $1.49M+998% | $40.05M+5,789% | -$2.29M-192% | -$1.19M-137% | ||
| -$12.16M-118% | -$18.87M-65.5% | -$44.08M— | -$5.48M-682% | -$5.58M+46.5% | ||
| -25.3%-13.0pp | -42.7%-15.2pp | -70.9%— | -10.5%-12.3pp | -12.2%+10.1pp | ||
| -$9.39M-7.5% | -$16.6M-26.7% | -$3.7M— | -$7.27M-203% | -$8.73M-30.0% | ||
| -19.5%-0.4pp | -37.6%-6.0pp | -6%— | -13.9%-9.3pp | -19.2%-4.7pp | ||
| -$11.4M-7.3% | -$18.46M-23.3% | -$5.59M— | -$9.19M-116% | -$10.62M-24.6% |
FAQ
- What is Cytek Biosciences, Inc.'s revenue?
- Cytek Biosciences, Inc. (CTKB) generated $206.7M in revenue over the trailing twelve months, up 5.4% year over year.
- Is Cytek Biosciences, Inc. profitable?
- Cytek Biosciences, Inc. is not currently profitable: it reported a net loss of $80.6M over the trailing twelve months, a -39.0% net margin.
- What are Cytek Biosciences, Inc.'s profit margins?
- Gross margin is 53.2% and operating margin is -21.6%, with a -39.0% net margin.
- What is Cytek Biosciences, Inc.'s earnings per share?
- Cytek Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-0.62.
- Where does Cytek Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
